Fingerprint
Dive into the research topics of 'Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Claudio Galarza, Diana Valencia, Gabriel J. Tobón, Luis Zurita, Rubén D. Mantilla, Ricardo Pineda-Tamayo, Adriana Rojas-Villarraga, Juan C. Rueda, Juan Manuel Anaya
Research output: Contribution to journal › Research Article › peer-review
76
Scopus
citations